- Home
- NAVI vs JANX Comparison
NAVI vs JANX Comparison
Compare NAVI & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAVI
- JANX
- Stock Information
- Founded
- NAVI 1973
- JANX 2017
- Country
- NAVI United States
- JANX United States
- Employees
- NAVI N/A
- JANX N/A
- Industry
- NAVI Investment Bankers/Brokers/Service
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- NAVI Finance
- JANX Health Care
- Exchange
- NAVI Nasdaq
- JANX Nasdaq
- Market Cap
- NAVI 1.4B
- JANX 1.4B
- IPO Year
- NAVI N/A
- JANX 2021
- Fundamental
- Price
- NAVI $13.97
- JANX $26.46
- Analyst Decision
- NAVI Hold
- JANX Strong Buy
- Analyst Count
- NAVI 7
- JANX 8
- Target Price
- NAVI $14.43
- JANX $90.63
- AVG Volume (30 Days)
- NAVI 953.3K
- JANX 787.8K
- Earning Date
- NAVI 07-28-2025
- JANX 08-06-2025
- Dividend Yield
- NAVI 4.53%
- JANX N/A
- EPS Growth
- NAVI N/A
- JANX N/A
- EPS
- NAVI 0.52
- JANX N/A
- Revenue
- NAVI $699,000,000.00
- JANX $9,336,000.00
- Revenue This Year
- NAVI N/A
- JANX N/A
- Revenue Next Year
- NAVI $0.56
- JANX $1,470.82
- P/E Ratio
- NAVI $27.26
- JANX N/A
- Revenue Growth
- NAVI N/A
- JANX 28.12
- 52 Week Low
- NAVI $10.53
- JANX $22.48
- 52 Week High
- NAVI $16.97
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- NAVI 48.65
- JANX 67.72
- Support Level
- NAVI $14.25
- JANX $24.80
- Resistance Level
- NAVI $14.94
- JANX $24.87
- Average True Range (ATR)
- NAVI 0.52
- JANX 1.15
- MACD
- NAVI -0.11
- JANX 0.50
- Stochastic Oscillator
- NAVI 15.17
- JANX 93.89
About NAVI Navient Corporation
Navient Corp provides technology-enabled education finance solutions that simplify complex programs and help millions of people achieve success. The company operates its business in three segments: Federal Education Loans, Consumer Lending, and Business Processing. A majority of its revenue is generated from the Federal Education Loans segment, in which the company owns and manages the Federal Family Education Loan Program (FFELP) loans, generating revenue mainly in the form of net interest income. The Consumer Lending segment owns and manages private education loans and is the master servicer for these portfolios. Through its Earnest brand, the company also refinances and originates in-school private educational loans.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.